President Trump makes an announcement

Key Concepts

• TrumpRx.gov: A new website launched to provide discounted prescription drugs to consumers.
• Most Favored Nation (MFN) Agreements: Agreements negotiated by the Trump administration to ensure the US pays the lowest price for drugs, equal to that paid by any other country.
• GLP-1s: A class of drugs used for weight loss (e.g., Ozempic, Wegovy).
• Tariffs: Used as leverage to encourage other countries to raise their drug prices, thereby lowering prices for the US.
• National Design Studio: A team responsible for the design and user experience of TrumpRx.gov.
• Subsidization: The claim that the US was previously subsidizing drug costs for the rest of the world.
• Drug Manufacturing Reshoring: Efforts to bring pharmaceutical manufacturing back to the United States.

Launch of TrumpRx.gov: Lowering Prescription Drug Costs

This transcript details the launch of TrumpRx.gov, a website designed to offer significant discounts on prescription drugs to American consumers. The initiative, presented by former President Donald Trump, is framed as a historic achievement in healthcare affordability, fulfilling a long-standing promise to lower drug prices.

The Problem of High Drug Prices

The core argument presented is that Americans have been paying disproportionately high prices for prescription drugs compared to the rest of the world. Trump asserts that the US, despite representing only 4% of the global population and consuming 13% of prescription drugs, accounts for 75% of pharmaceutical companies’ revenue. He characterizes this as the US effectively “subsidizing the entire world” to the tune of hundreds of billions of dollars annually. He states, “The American people were effectively subsidizing the cost of drugs for the entire world. And it's not going to happen any longer. We ended it.”

The Most Favored Nation (MFN) Approach

The central strategy to address this issue is the implementation of “Most Favored Nation” (MFN) agreements. These agreements, negotiated by the Trump administration, aim to ensure that the US pays no more for a drug than the lowest price paid by any other country. Trump explains that this was achieved, in part, through the use of tariffs. He threatened to impose tariffs on nations that did not raise their drug prices, incentivizing them to align with US pricing. “I said, 'If you don't put them up, then we're going to put tariffs on your nation, which would be more expensive to you.'” He claims this resulted in drug costs increasing by double, triple, or even more in other countries, while simultaneously decreasing significantly in the US.

Specific Drug Price Reductions

The launch event highlights several specific examples of dramatic price reductions:

• Ozempic (Novo Nordisk): Reduced from over $1,000 to $199 (a 578% difference).
• Wegovy (Novo Nordisk): Reduced from over $1,300 to $199.
• Insulin (Eli Lilly): Reduced from $200 to $25.
• Asthma Inhaler (AstraZeneca): Reduced from $458 to $51 (nearly 800% difference).
• Gonal F (EMD Serono - IVF drug): Price reduction not explicitly stated, but described as moving from the highest price in the developed world to the lowest.

These reductions are presented as unprecedented and indicative of the initiative’s success. Trump projects that Americans will save “tremendous amounts of money,” with discounts ranging from 300% to 600% or even higher.

Expanding the Initiative & Manufacturing Reshoring

The administration claims that 16 of the 17 largest pharmaceutical companies have signed agreements committing to MFN pricing for all new drugs brought to market in the US. The remaining company is expected to follow suit. Furthermore, the administration highlights efforts to incentivize pharmaceutical companies to bring manufacturing back to the US through the use of tariffs. Companies avoiding US manufacturing face “very big penalties in the form of tariffs.” Eli Lilly is cited as an example, building six plants in the US with billions of dollars in investment. Trump states that this is resulting in “jobs, economic growth, factory openings, and far greater national security.” He claims over $18 trillion is flowing into the US due to these policies.

Website Functionality & User Experience

Joe Gebbia, Chief Design Officer of the United States, and Dr. Mehmet Oz demonstrate the functionality of TrumpRx.gov. The website allows users to search for drugs, find coupons, and identify pharmacies where the discounted prices are available. The site is described as “intelligent,” surfacing commonly prescribed drugs alongside the searched medication. Katherine, a military spouse navigating infertility treatments, shares her personal story, emphasizing the financial burden of IVF and the potential impact of the discounted medication prices on families like hers. She states, “These efforts help ensure that IVF remains within reach for families who are doing everything that they can to build a future.”

Projected Outcomes & Future Expansion

The administration projects that the initiative will lead to significant health improvements, including a projected loss of 100 million pounds among Americans due to the reduced cost of weight loss medications. The website currently offers discounts on over 40 medications, with plans to add more “week over week.”

Conclusion

The launch of TrumpRx.gov is presented as a landmark achievement in lowering prescription drug prices for Americans. The initiative relies on MFN agreements, leveraging tariffs to incentivize lower prices, and a user-friendly website to facilitate access to discounts. The administration emphasizes the potential for significant cost savings, improved health outcomes, and a revitalization of domestic pharmaceutical manufacturing. The core message is a shift from the US subsidizing the rest of the world to prioritizing American consumers and securing the lowest possible drug prices.